Biote Schedules First Quarter 2024 Financial Results Release and Conference Call
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the
BusinesswireApr 23 16:05 ET
B. Riley Ups Price Target on Biote to $10 From $9, Maintains Buy Rating
Biote (BTMD) has an average rating of buy and price targets ranging from $7 to $10, according to analysts polled by Capital IQ. Price: 5.6, Change: -0.15, Percent Change: -2.61
MT NewswiresApr 5 09:27 ET
Correction: --B. Riley Lowers Bitcoin Depot's Price Target to $4 From $6, Maintains Buy Rating
(Corrected with the BTM ticker and Bitcoin Depot name in the headline.)
MT NewswiresApr 3 10:24 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersQilian Intl Hldg Gr (NASDAQ:QLI) shares rose 63.8% to $1.04 during Friday's after-market session. The market value of their outstanding shares is at $37.1 million. Sunshine Biopharma (NASDAQ:SB
BenzingaMar 29 16:30 ET
Optimistic Outlook: Biote's Growth Potential and Strategic Initiatives Despite Transitional Challenges
TipRanksMar 14 21:15 ET
Biote Corp. Releases March 2024 Investor Presentation
TipRanksMar 14 16:24 ET
Express News | Biote Shares Are Trading Higher After the Company Reported Better-than-expected Q$ GAAP EPS Results
Moomoo 24/7Mar 13 13:52 ET
Biote Soars 22% With Expected Acceleration in 2H 2024 Sales
By Emon Reiser Shares of Biote were rising sharply after the hormone therapy company on Tuesday reaffirmed its financial guidance and said it expects growth to accelerate in the second half of the ye
WSJMar 13 12:13 ET
Roth MKM Reiterates Buy on Biote, Raises Price Target to $9
Roth MKM analyst George Kelly reiterates Biote with a Buy and raises the price target from $8 to $9.
Analyst UpgradesMar 13 11:12 ET
Biote Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/13/2024 39.97% Roth MKM $8 → $9 Reiterates Buy → Buy 02/20/2024 39.97% B. Riley Securities → $9 Initiat
BenzingaMar 13 11:09 ET
Solid Biosciences, Cue Biopharma, Annexon Among Healthcare Movers
Seeking AlphaMar 13 10:00 ET
Biote Corp. (PNK:BTMD) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 13 08:37 ET
Analysts Are Bullish on Top Healthcare Stocks: Biote (BTMD), Incyte (INCY)
TipRanksMar 13 07:40 ET
Earnings Call Summary | Biote(BTMD.US) Q4 2023 Earnings Conference
The following is a summary of the Biote Corp. (BTMD) Q4 2023 Earnings Call Transcript:Financial Performance:Biote Corp reported Q4 adjusted EBITDA increase of approximately 3%.In 2023, the company ach
moomoo AIMar 12 21:16 ET · Conference Call
Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M
Previously, Biote projected fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million. First half 2024 consolidated year-on-year revenue growth is expected to be
BenzingaMar 12 16:52 ET
Biote: Q4 Earnings Insights
Biote (NASDAQ:BTMD) reported its Q4 earnings results on Tuesday, March 12, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsBiote beat estimated earnings by 125.0%, r
BenzingaMar 12 16:15 ET
Biote Q4 2023 GAAP EPS $0.18 Beats $0.08 Estimate, Sales $45.703M Miss $45.740M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.08 by 125 percent. This is unchanged from the same period last year. The company rep
BenzingaMar 12 16:13 ET
Biote Sees 2024 Rev $200M-$204M >BTMD
Biote Sees 2024 Rev $200M-$204M >BTMD
Dow JonesMar 12 16:08 ET
Biote in Agreement to Repurchase 18.4M Founders' Shrs in Addition to Separate $20M Shr Repurchase Program
Biote in Agreement to Repurchase 18.4M Founders' Shrs in Addition to Separate $20M Shr Repurchase Program
Dow JonesMar 12 16:06 ET
Press Release: Biote Reports Fourth Quarter and Full Year 2023 Financial Results
Biote Reports Fourth Quarter and Full Year 2023 Financial Results Grew practitioner network to over 7,100 from 6,400 in 2022 Launched BioteRx, our new hormone and therapeutic wellness offerings Enh
Dow JonesMar 12 16:05 ET
No Data
No Data